Los Angeles Capital Management LLC Buys 43 Shares of Danaher Co. (NYSE:DHR)

Los Angeles Capital Management LLC increased its stake in shares of Danaher Co. (NYSE:DHR) by 1.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,470 shares of the conglomerate’s stock after purchasing an additional 43 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Danaher were worth $803,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Natixis Advisors L.P. boosted its holdings in shares of Danaher by 4.5% in the 4th quarter. Natixis Advisors L.P. now owns 610,312 shares of the conglomerate’s stock valued at $141,188,000 after buying an additional 26,147 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in Danaher by 4.3% in the fourth quarter. Commonwealth Equity Services LLC now owns 149,379 shares of the conglomerate’s stock worth $34,557,000 after purchasing an additional 6,158 shares during the last quarter. Fisher Asset Management LLC grew its holdings in Danaher by 6.2% in the fourth quarter. Fisher Asset Management LLC now owns 4,227,108 shares of the conglomerate’s stock worth $977,900,000 after purchasing an additional 248,140 shares during the last quarter. LGT Group Foundation lifted its holdings in shares of Danaher by 21.6% during the 4th quarter. LGT Group Foundation now owns 40,182 shares of the conglomerate’s stock valued at $9,368,000 after purchasing an additional 7,138 shares during the last quarter. Finally, Wilbanks Smith & Thomas Asset Management LLC boosted its position in shares of Danaher by 14.2% in the 4th quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 65,661 shares of the conglomerate’s stock worth $15,190,000 after purchasing an additional 8,178 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In related news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The disclosure for this sale can be found here. Insiders sold a total of 103,984 shares of company stock worth $25,997,094 in the last 90 days. Insiders own 10.90% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on DHR shares. Robert W. Baird upped their target price on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Raymond James lifted their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Barclays boosted their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. Finally, TD Cowen raised their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $267.31.

Danaher Price Performance

Shares of Danaher stock opened at $251.48 on Friday. The firm has a market cap of $186.27 billion, a PE ratio of 42.62, a P/E/G ratio of 3.82 and a beta of 0.83. The business has a 50-day moving average price of $248.15 and a 200 day moving average price of $233.30. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business’s quarterly revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.36 EPS. Sell-side analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.